Anogenital Wart Burden and Cost of Illnesses

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-30

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will be a prospective study of patients presenting with anogenital warts. The objective are to assess proportion of anogenital warts to the total number of sexual transmitted infection patients, to quantify direct and indirect cost of illnesses and psychological burden associated with anogenital warts and to estimate government program expenditure for the prevention and control and treatment of the STI/anogenital HPV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile

NCT01483794

Condylomata Acuminata

UNKNOWN

The Role of Genital Warts in HIV Acquisition in Peru

NCT01387412

Anogenital Warts HIV

COMPLETED

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

NCT01532102

Anogenital Warts Condylomata Acuminata Human Papillomavirus Infection

COMPLETED PHASE1/PHASE2

Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient

NCT06587542

Anogenital Warts HIV Infection Tuberculin Purified Protein Derivative

NOT_YET_RECRUITING PHASE2/PHASE3

The Psychosocial and Economic Burden of Genital Warts

NCT01520194

Female Genital Warts

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An observational study, multiple visit, 2-center study will be conducted in Rajavithi General Hospital, and Bangrak Hospital. One hundred and fifty subjects will be enrolled from both hospitals. Anogenital wart patients presented in Rajavithi General Hospital and the STI clinic at Bangrak Hospital will be recruited prospectively. All patients will be treated according to standard medical guidelines or usual care of the institutes. After the baseline assessment, the patients will have follow up visits with their physicians and will also be interviewed at the clinical sites three time approximately at day 7 (-2+7 days), month 1 (+-7 days), and month 6 (+-7 days) until they are cure. At month 6 (+-14 days), telephone assessment for the capture of any signs of disease recurrence will be done. All patients will be followed for 6 months under the same schedule.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Warts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is 18 years of age or older and has anogenital warts
* Physician confirmed clinical diagnosis of anogenital warts
* Subject is capable of understanding the study and the content of the consent form and has agreed to participate in the study by signing the informed consent
* Subject will be available for the study follow up period

Exclusion Criteria

* Subject is unable to give informed consent
* Subject has any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives such as other concurrent/active STI

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No